Jennifer Gao

1.8k total citations
34 papers, 891 citations indexed

About

Jennifer Gao is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Economics and Econometrics. According to data from OpenAlex, Jennifer Gao has authored 34 papers receiving a total of 891 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 10 papers in Economics and Econometrics. Recurrent topics in Jennifer Gao's work include Advanced Breast Cancer Therapies (9 papers), Health Systems, Economic Evaluations, Quality of Life (8 papers) and Cancer Treatment and Pharmacology (7 papers). Jennifer Gao is often cited by papers focused on Advanced Breast Cancer Therapies (9 papers), Health Systems, Economic Evaluations, Quality of Life (8 papers) and Cancer Treatment and Pharmacology (7 papers). Jennifer Gao collaborates with scholars based in United States, United Kingdom and Singapore. Jennifer Gao's co-authors include Sandra M. Swain, Julia A. Beaver, Richard Pazdur, Laleh Amiri‐Kordestani, Erik Bloomquist, Rajeshwari Sridhara, Valerie Voon, Mark Hallett, Christina Brezing and Vindhya Ekanayake and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Brain.

In The Last Decade

Jennifer Gao

28 papers receiving 875 citations

Peers

Countries citing papers authored by Jennifer Gao

Since Specialization

Citations

This map shows the geographic impact of Jennifer Gao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Gao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Gao more than expected).

Fields of papers citing papers by Jennifer Gao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Gao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Gao. The network helps show where Jennifer Gao may publish in the future.

Co-authorship network of co-authors of Jennifer Gao

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Gao. A scholar is included among the top collaborators of Jennifer Gao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Gao. Jennifer Gao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	U.S. FDA analysis of enrollment of Asian patients from India in cancer clinical trials leading to approval from 2010 to 2022. 2024 ·Journal of Clinical Oncology ·Geetika Srivastava, Rupert W. Leong, Abhilasha Nair, Bindu Kanapuru, Fatima Rizvi, (unknown), Jennifer J. Lee, Suparna Wedam, Asma Dilawari, (unknown), (unknown), (unknown), Clara Lee, Donna R. Rivera, Steven J. Lemery, Jennifer Gao, Tamy Kim, Richard Pazdur	1
2	FDA Approval Summary: Capecitabine Labeling Update under Project Renewal 2024 ·Clinical Cancer Research ·Sundeep Agrawal, (unknown), William F. Pierce, (unknown), (unknown), Melanie Royce, Christy Osgood, Laleh Amiri‐Kordestani, Haw-Jyh Chiu, Tiffany K. Ricks, (unknown), Jeanne Fourie Zirkelbach, Rosane Charlab, Michael Pacanowski, Tamy Kim, Richard Pazdur, Paul G. Kluetz, Jennifer Gao	0
3	FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer 2023 ·Clinical Cancer Research ·Jennifer Gao, Christy Osgood, (unknown), Erik Bloomquist, Shenghui Tang, (unknown), Tiffany K. Ricks, (unknown), William F. Pierce, Donna R. Rivera, Richard Pazdur, Paul G. Kluetz, Laleh Amiri‐Kordestani	3
4	The Development of the Oncology Center of Excellence Patient-Friendly Language Glossary of Oncology Clinical Trial Terms 2023 ·The Oncologist ·(unknown), Janice Kim, Jennifer Gao, Laleh Amiri‐Kordestani, Julia A. Beaver, Paul G. Kluetz	0
5	Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis 2021 ·The Lancet Oncology ·Jennifer Gao, Joyce Cheng, Tatiana M. Prowell, Erik Bloomquist, Shenghui Tang, Suparna Wedam, Melanie Royce, (unknown), Christy Osgood, Gwynn Ison, Rajeshwari Sridhara, Richard Pazdur, Julia A. Beaver, Laleh Amiri‐Kordestani	21
6	US Food and Drug Administration Analysis of Patient-Reported Diarrhea and Its Impact on Function and Quality of Life in Patients Receiving Treatment for Breast Cancer 2021 ·Value in Health ·Tingyu Chen, Bellinda L. King‐Kallimanis, (unknown), (unknown), Mallorie H. Fiero, Jennifer Gao, Julia A. Beaver, Vishal Bhatnagar, Paul G. Kluetz	1
7	Model Development of CDK4/6 Predicted Efficacy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer 2021 ·JCO Clinical Cancer Informatics ·Jeremy Mason, Yutao Gong, Laleh Amiri‐Kordestani, Suparna Wedam, Jennifer Gao, Tatiana M. Prowell, Harpreet Singh, Anup Amatya, Shenghui Tang, Richard Pazdur, Peter Kühn, Gideon M. Blumenthal, Julia A. Beaver	2
8	FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs 2020 ·Clinical Cancer Research ·Paul G. Kluetz, Patricia Keegan, George D. Demetri, Katherine A. Thornton, Joohee Sul, (unknown), (unknown), Laurie B. Burke, R. Donald Harvey, (unknown), Sundeep Agrawal, Abhilasha Nair, Martha Donoghue, William F. Pierce, Stacy S. Shord, Jennifer Gao, Richard Pazdur	8
9	U.S. Food and Drug Administration: Initial Experience with the Real-Time Oncology Review Program 2020 ·Clinical Cancer Research ·R. Angelo de Claro, Jennifer Gao, Tamy Kim, Paul G. Kluetz, Marc R. Theoret, Julia A. Beaver, Richard Pazdur	12
10	Patient-reported diarrhea impact on physical functioning and quality of life in clinical trial data submitted to the U.S. Food and Drug Administration. 2020 ·Journal of Clinical Oncology ·Ting‐Yu Chen, Bellinda L. King‐Kallimanis, (unknown), Mallorie H. Fiero, Jennifer Gao, Julia A. Beaver, Vishal Bhatnagar, Paul G. Kluetz	1
11	FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer 2020 ·The Oncologist ·Shaily Arora, Sanjeeve Balasubramaniam, Hui Zhang, Tara Berman, Preeti Narayan, Daniel L. Suzman, Erik Bloomquist, Shenghui Tang, Yutao Gong, Rajeshwari Sridhara, Francisca Reyes Turcu, Deb Chatterjee, (unknown), Soma Ghosh, Reena Philip, Anand Pathak, Jennifer Gao, Laleh Amiri‐Kordestani, Richard Pazdur, Julia A. Beaver	127
12	CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis 2019 ·The Lancet Oncology ·Jennifer Gao, Joyce Cheng, Erik Bloomquist, (unknown), Suparna Wedam, Harpreet Singh, Laleh Amiri‐Kordestani, Amna Ibrahim, Rajeshwari Sridhara, Kirsten B. Goldberg, Marc R. Theoret, Paul G. Kluetz, Gideon M. Blumenthal, Richard Pazdur, Julia A. Beaver, Tatiana M. Prowell	194
13	P3.03-05 Comparative Transcriptomic Analysis of Lung-iPSC, NSCLC, and SCLC: Potential Implications for iPSC Modeling of Lung Cancer 2018 ·Journal of Thoracic Oncology ·Vivek Shukla, (unknown), Jennifer Gao, (unknown), Julie A. Hong, M. Zhang, (unknown), Huann‐Sheng Chen, David S. Schrump	1
14	Luminal A Breast Cancer and Molecular Assays: A Review 2018 ·The Oncologist ·Jennifer Gao, Sandra M. Swain	164
15	Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab 2017 ·Annals of Oncology ·Sandra M. Swain, Andreas Schneeweiß, Luca Gianni, Jennifer Gao, (unknown), Maeve Waldron-Lynch, Sarah Heeson, (unknown), (unknown), Javier Cortés, José Baselga	25
16	HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens 2016 ·Clinical Breast Cancer ·Jennifer Gao, Ming Tan, Paula R. Pohlmann, Sandra M. Swain	14
17	The Role of Social Novelty in Risk Seeking and Exploratory Behavior: Implications for Addictions 2016 ·PLoS ONE ·Simon Mitchell, Jennifer Gao, Mark Hallett, Valerie Voon	7
18	Pertuzumab for the treatment of breast cancer: a safety review 2016 ·Expert Opinion on Drug Safety ·Jennifer Gao, Sandra M. Swain	15
19	Does CDKN2A Loss Predict Palbociclib Benefit? 2015 ·Current Oncology ·Jennifer Gao, (unknown), Sandra M. Swain	14
20	Dopamine agonists and risk: impulse control disorders in Parkinson's; disease 2011 ·Brain ·Valerie Voon, Jennifer Gao, Christina Brezing, Mkael Symmonds, Vindhya Ekanayake, Hubert Fernandez, Raymond J. Dolan, Mark Hallett	163

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact